종양학 바이오시밀러 시장 : 제품 유형별, 치료 적응증별, 투여 경로별, 환자 연령층별, 유통 채널별 시장 예측(2026-2032년)

The Oncology Biosimilars Market is projected to grow by USD 18.38 billion at a CAGR of 13.04% by 2032.

Oncology Biosimilars Market Introduction

Oncology biosimilars are reshaping cancer care by providing highly similar, clinically comparable alternatives to reference biologics used in solid tumors, hematologic malignancies, and supportive care. Regulators, including the U.S. FDA, European Medicines Agency, World Health Organization, and national agencies, require a totality-of-evidence approach covering analytical similarity, pharmacokinetics, immunogenicity, and clinical performance before approval.

Demand is supported by patent expirations for major monoclonal antibodies, pressure on oncology drug budgets, and payer interest in sustainable access. Biosimilars for trastuzumab, bevacizumab, rituximab, and pegfilgrastim have demonstrated that competition can expand treatment affordability while preserving the standards clinicians expect for biologic cancer therapies.

Transformative Shifts in the Oncology Biosimilars Landscape

The landscape is shifting from first-wave biosimilar launches toward lifecycle-based competition, portfolio contracting, and evidence-driven adoption. Hospitals and oncology networks are increasingly evaluating biosimilars through therapeutic interchange protocols, formulary governance, real-world outcomes, and total cost-of-care measures rather than acquisition price alone.

Regulatory maturity is also transforming the market. Europe's long-standing biosimilar framework, the FDA's expanding oncology biosimilar approvals, and growing reliance pathways in emerging markets are reducing uncertainty. At the same time, manufacturing scale, supply assurance, physician education, and patient confidence remain decisive differentiators for organizations competing in oncology biologics.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is adding cumulative value across oncology biosimilar development, manufacturing, and commercialization. AI-enabled analytics support cell-line optimization, process monitoring, deviation detection, regulatory intelligence, literature surveillance, and pharmacovigilance signal detection, helping teams manage complex biologic variability with greater speed and consistency.

The impact is strongest when AI complements validated scientific methods rather than replacing them. Regulators continue to rely on robust comparability evidence, quality-by-design controls, and post-market safety monitoring. As FDA and EMA policy discussions on AI in drug development evolve, organizations that pair advanced analytics with transparent governance are better positioned to improve timelines, compliance, and launch execution.

Key Regional Insights Across Major Oncology Biosimilar Markets

North America remains a high-value oncology biosimilars region, led by the United States, where Medicare Part B reimbursement dynamics, integrated delivery networks, oncology practice pathways, and payer contracting influence utilization. Canada is advancing through provincial and pan-Canadian policy mechanisms that increasingly favor cost-effective biologic options while maintaining Health Canada's rigorous biosimilar review standards.

Europe is the most mature adoption environment, supported by EMA experience dating back to the first EU biosimilar approval in 2006, national tendering, physician familiarity, and established pharmacovigilance systems. Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia combine regulatory modernization with local biologics manufacturing capacity, oncology infrastructure investment, and increasing acceptance of biosimilar monoclonal antibodies. Latin America is growing through ANVISA, COFEPRIS, and regional access initiatives that prioritize affordability and public-sector procurement. The Middle East is advancing through national cancer strategies, hospital modernization, and centralized purchasing, while Africa shows rising demand through oncology capacity building, donor-supported access programs, public procurement, and growing recognition of biosimilars as tools for improving biologic cancer therapy availability.

Key Group Insights for Oncology Biosimilar Adoption

The European Union anchors global biosimilar confidence through harmonized scientific assessment, pharmacovigilance, interchangeability guidance, and widespread tender-based purchasing. G7 countries remain central to clinical evidence generation, reimbursement innovation, advanced oncology care delivery, and premium biologic demand, while NATO members overlap with many high-income health systems focused on supply security, procurement resilience, and uninterrupted access to essential oncology medicines.

BRICS markets are increasingly important because China, India, Brazil, Russia, and South Africa combine large oncology populations with industrial policy supporting biologics manufacturing, technology transfer, and domestic medicine security. ASEAN countries are improving regulatory convergence, reliance pathways, and hospital access to cost-efficient biologics, while the GCC is using centralized procurement, specialist cancer centers, and national oncology strategies to accelerate availability of oncology biosimilars across public and private health systems.

Key Country Insights Shaping Competitive Positioning

The United States remains the largest commercial opportunity, driven by reference biologic spending, oncology network consolidation, Medicare reimbursement rules, and growing clinician experience with FDA-approved biosimilars. Canada is expanding access through provincial reimbursement policies and pan-Canadian review mechanisms, while Mexico is strengthening biosimilar use through public procurement and COFEPRIS oversight. Brazil combines large oncology demand with established ANVISA regulation and public health system purchasing, making it a key Latin American access market.

The United Kingdom, Germany, France, Italy, and Spain benefit from mature oncology infrastructure, specialist prescribing capacity, and national health technology assessment, although adoption varies by tendering, gainsharing, hospital formularies, and prescribing autonomy. Russia emphasizes localized supply and medicine security. China and India are pivotal manufacturing and demand centers, supported by large patient populations, domestic biologics capabilities, and evolving regulatory pathways. Japan, South Korea, and Australia maintain rigorous regulatory standards and strong oncology systems, making them influential reference markets for quality expectations, switching practices, real-world evidence, and physician acceptance.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize oncology biosimilar portfolios around high-burden cancer indications, reference-product loss of exclusivity, regulatory feasibility, and payer willingness to shift volume. Commercial success requires more than price reduction; organizations need reliable supply, oncology-specific medical education, patient support, transparent switching data, and contracting models aligned with provider economics.

Manufacturers should invest in advanced characterization, scalable biologics manufacturing, quality systems, pharmacovigilance readiness, and real-world evidence generation. Partnerships with hospitals, group purchasing organizations, cancer networks, and national health systems can accelerate uptake. In emerging markets, local regulatory expertise, cold-chain reliability, stakeholder education, and affordability programs are essential for sustainable oncology biosimilar adoption.

Research Methodology

The analysis is built on triangulated secondary and primary research. Secondary sources include regulatory databases, product labels, peer-reviewed oncology literature, health technology assessment publications, reimbursement policies, clinical guidelines, pharmacovigilance documents, and guidance from FDA, EMA, WHO, and national authorities.

Market interpretation is validated through expert review of competitive launches, approval pathways, manufacturing capacity, pricing behavior, procurement practices, reimbursement frameworks, and adoption trends. The research applies structured data normalization, cross-source verification, evidence weighting, and quality checks to ensure insights reflect verified, data-backed market behavior rather than unverified assumptions, without relying on market sizing, market share, or forecasting.

Conclusion

Oncology biosimilars have moved from proof-of-concept to an established pillar of cancer-care affordability. Their continued adoption is supported by regulatory confidence, expanding clinical familiarity, payer pressure, public procurement, and the ongoing need to manage biologic oncology spending without compromising treatment standards.

The next phase will reward organizations that combine scientific rigor, manufacturing reliability, AI-enabled operational efficiency, strong pharmacovigilance, and region-specific market access strategies. Stakeholders that build trust with oncologists, payers, regulators, pharmacists, and patients will be best positioned to capture long-term value in the global oncology biosimilars market.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Oncology Biosimilars Market, by Product Type

• 7.1. Monoclonal Antibodies
  • 7.1.1. Rituximab
  • 7.1.2. Trastuzumab
  • 7.1.3. Bevacizumab
• 7.2. Hormonal Therapies
• 7.3. Growth Factors
  • 7.3.1. Filgrastim
  • 7.3.2. Pegfilgrastim

8. Oncology Biosimilars Market, by Therapeutic Indication

• 8.1. Breast Cancer
• 8.2. Colorectal Cancer
• 8.3. Gastric Cancer
• 8.4. Lung Cancer
• 8.5. Non-Hodgkin's Lymphoma

9. Oncology Biosimilars Market, by Route Of Administration

• 9.1. Intravenous Infusion
• 9.2. Subcutaneous Injection

10. Oncology Biosimilars Market, by Patient Age Group

• 10.1. Pediatric Patients
• 10.2. Adult Patients
• 10.3. Geriatric Patients

11. Oncology Biosimilars Market, by Distribution Channel

• 11.1. Hospital Pharmacies
• 11.2. Online Pharmacies
• 11.3. Retail Pharmacies
• 11.4. Specialty Pharmacies

12. Oncology Biosimilars Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Oncology Biosimilars Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Oncology Biosimilars Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Accord Healthcare Ltd.
• 16.2. Alkem Laboratories Ltd.
• 16.3. Amgen Inc.
• 16.4. Apotex Inc.
• 16.5. BIOCAD
• 16.6. Biocon Biologics Limited
• 16.7. Celltrion Inc.
• 16.8. Coherus BioSciences, Inc.
• 16.9. Dr. Reddy's Laboratories Ltd.
• 16.10. Henlius Biopharmaceuticals Co., Ltd.
• 16.11. Hospira Inc.
• 16.12. Intas Pharmaceuticals Ltd.
• 16.13. Novartis International AG
• 16.14. Organon & Co.
• 16.15. Pfizer Inc.
• 16.16. Sandoz Group AG
• 16.17. STADA Arzneimittel AG
• 16.18. Teva Pharmaceutical Industries Ltd.
• 16.19. Viatris Inc.
• 16.20. Zydus Lifesciences Ltd.